This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Case Series

Metformin for Weight Loss and Control in Patients With Mood Disorder

Jonas L. Linneke, MD; Gitte K. Jørgensen, MD; and Claudio Csillag, MD, PhD

Published: October 28, 2014

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Two-thirds of patients in long-term treatment with a second-generation antipsychotic (SGA) experience weight gain. Weight gain might be due to receptor blockade to H1 receptors (as with tricyclic antidepressants) and to 5-HT2C receptors, impaired metabolic regulation, down-regulation of appetite suppression, and less physical activity due to sedation. Metformin promotes the decrease of glucose absorption, suppression of gluconeogenesis in liver, stimulation of glucose uptake in skeletal muscle, and augmentation of insulin activity.

Volume: 75

Quick Links: Side Effects-Medication , Weight

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...